top of page

Rheumatoid arthritis

Basic Information

Market Information

Currently Approved Drugs 

Image 1 

Chart

Image 2 

Chart

Current Catalysts in AMP Databases

IGMS

Imvotamab (IGM-2323) (CD20 x CD3)

Rheumatoid arthritis (RA)

Phase 1b

TBA

XBIT

Natrunix

Rheumatoid Arthritis (RA)

Phase 2

TBA

RIGL

R289

Lower-risk myelodysplastic syndrome (LR-MDS)

Phase 1b

YE 2024

bottom of page